Bevacizumab and Capecitabine as First-Line Therapy in Treating Older Patients With Metastatic Colorectal Cancer
Status:
Terminated
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of colorectal cancer by blocking blood flow to the tumor. Drugs used in chemotherapy,
such as capecitabine, work in different ways to stop the growth of tumor cells, either by
killing the cells or by stopping them from dividing. Giving bevacizumab together with
capecitabine may kill more tumor cells.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with
capecitabine works as first-line therapy in treating older patients with metastatic
colorectal cancer.